For Candida auris infection resistant to amphotericin B and fluconazole, what is the recommended caspofungin dosing regimen and duration of therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Caspofungin Dosing for Multidrug-Resistant Candida auris

For Candida auris resistant to both amphotericin B and fluconazole, administer caspofungin 70 mg IV loading dose on Day 1, followed by 50 mg IV daily for 2-3 weeks, with treatment duration extending until at least 14 days after the last positive blood culture and resolution of clinical symptoms.

Dosing Regimen

Standard Adult Dosing

  • Loading dose: 70 mg IV on Day 1
  • Maintenance dose: 50 mg IV once daily
  • Administration: Slow IV infusion over approximately 1 hour 1

Duration of Therapy

The most recent guidelines provide clear duration parameters 2:

  • Minimum duration: 2-3 weeks for fluconazole-resistant species
  • Extended duration: Continue for at least 14 days after the last positive blood culture 3
  • Clinical endpoint: Treat until resolution of all signs and symptoms

If the 50 mg dose is well tolerated but clinical response is inadequate, increase to 70 mg daily 1. This dose escalation strategy is supported by both FDA labeling and clinical experience with refractory infections 4.

Rationale for Caspofungin in C. auris

C. auris demonstrates alarmingly high resistance rates: 96.49% to fluconazole and 72.81% to amphotericin B, but only 25.89% to caspofungin 5. This makes echinocandins like caspofungin the preferred first-line agents for multidrug-resistant C. auris infections.

The 2026 European Association of Urology guidelines specifically recommend caspofungin for fluconazole-resistant Candida species, including both localized and systemic infections 2. While these guidelines focus on urinary tract infections, the dosing principles apply to all invasive candidiasis.

Special Considerations

Hepatic Impairment

  • Mild impairment (Child-Pugh 5-6): No adjustment needed
  • Moderate impairment (Child-Pugh 7-9): Reduce to 35 mg daily after standard 70 mg loading dose 1

Renal Impairment

No dosage adjustment required regardless of creatinine clearance 2, 1

Pediatric Dosing (if applicable)

  • Loading dose: 70 mg/m² (maximum 70 mg)
  • Maintenance: 50 mg/m² daily (maximum 70 mg) 1

Critical Clinical Pitfalls

  1. Don't skip the loading dose: The 70 mg loading dose is essential for rapidly achieving therapeutic levels, particularly in critically ill patients 1

  2. Monitor for breakthrough resistance: While caspofungin resistance in C. auris is relatively low (25.89%), it does occur. Consider combination therapy with posaconazole if clinical response is inadequate, as this combination shows synergistic activity 6

  3. Source control is mandatory: Remove all intravascular catheters and address any other sources of infection 3, 7. Antifungal therapy alone is insufficient without source control

  4. Extended therapy may be necessary: For patients with persistent neutropenia, prolonged ICU stays, or complicated infections, treatment duration often exceeds the minimum 2-3 weeks 2, 3

Monitoring Parameters

  • Clinical response: Daily assessment of fever, hemodynamic stability, and organ function
  • Microbiological clearance: Repeat blood cultures every 48-72 hours until negative
  • Treatment endpoint: Continue therapy for at least 14 days after documented clearance and clinical improvement 3, 7

The evidence strongly supports caspofungin as the optimal choice for multidrug-resistant C. auris, with the standard loading dose/maintenance regimen providing effective therapy when combined with appropriate source control and adequate treatment duration 2, 1, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.